News | January 12, 2026
Novartis to open Florida radioligand facility
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The approval is backed by data showing deep, durable responses and manageable tolerability
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Subscribe To Our Newsletter & Stay Updated
